CLSA released a research report stating that TIGERMED's (03347) Q3 performance reflects a moderate recovery in its business. While margins remain under pressure, the firm expects a potential rebound in product performance by 2026. CLSA largely maintained its revenue forecasts for 2025–2027 but adjusted net profit projections—up 28.9% for 2025 and down 14.6% and 14.1% for 2026 and 2027, respectively—to reflect margin outlook. The target price was revised down from HK$58.9 to HK$52.1, retaining an "Outperform" rating.